AI
Tuesday, March 26, 2013 9:09:36 PM
Timeline
4-30-2012: Regen BioPharma, a subsidiary of BMSN, is formed.
5-8-2012: J. Christopher Mizer hired as President and COO.
6-6-2012: David White MD, Wei-Ping Min MD/PHD, and Vald Bogin MD are appointed as members of the Scientific Advisory Board.
6-7-2012: Granted access to patent for stimulating blood cell production with stem cells.
6-15-2012: David Audley joins the advisory board.
6-26-2012: Thomas E. Ichim PhD joins as Chief Scientific Officer and Director of Research.
10-29-2012: BMSN participates in the 2012 Stem Cell Meeting on the Mesa. There, J. Christopher Mizer explains their business plan. Check it out!
11-19-2012: Pre-Clinical study for HemaXellerate begins.
1-24-2013: Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate.
2-5-2013: Investigational New Drug (IND) Application is filed with the FDA for HemaXellerate.
2-26-2013: A Letter of Intent (LOI) is entered into to purchase a patent for a gene silencing treatment for breast cancer.
3-12-2013: BMSN settles an old lawsuit it had.
3-18-2013: Receives the IND # from the FDA for HemaXellerate.
3-22-2013: All SEC financials are brought up-to-date and BMSN is up-listed from the Pinks to the OTC-QB.
Where we're at now
- After the IND # PR was released, there was an initial surge in PPS. But once people realized this wasn't the full IND APPROVAL some flippers moved on to the next play and the price dropped a bit.
- Some more people moved on, dropping us below a penny which caused a panic sell-off.
- That panic caused us to dip below 50 MA and shorts and people looking for cheap shares used that to induce more fear and cause a 2nd wave of panic selling.
- Today savvy investors waited like sharks at the 200MA and sniped off millions of shares. 30+ million were grabbed in 2 minutes once it hit the 200MA, which started the bounce back up.
- Once the bounce started to take form, people on the sidelines got in and now we're in full bounce mode.
Here's the chart:
Looking Forward
- Aplastic Anemia has been shown to qualify for "Orphan Drug" status. Once the IND is approved, applying for this seems likely.
- There's also a new "Breakthrough" status that the FDA has. I'm not sure if HemaXellerate qualifies, but it sounds like it may. If so, they'll probably apply for this too. If granted, it allows the treatment to become approved for market in a single round of studies, instead of the normal three!
- Clinical trials will begin for HemaXellerate on 10 human subjects.
- The gene silencing treatment for breast cancer patent is acquired, kicking off a whole new chain of events.
IMO, we should be at least at 0.01 right now, if not at multiple pennies.
BMSN! Come get some!
4-30-2012: Regen BioPharma, a subsidiary of BMSN, is formed.
5-8-2012: J. Christopher Mizer hired as President and COO.
6-6-2012: David White MD, Wei-Ping Min MD/PHD, and Vald Bogin MD are appointed as members of the Scientific Advisory Board.
6-7-2012: Granted access to patent for stimulating blood cell production with stem cells.
6-15-2012: David Audley joins the advisory board.
6-26-2012: Thomas E. Ichim PhD joins as Chief Scientific Officer and Director of Research.
10-29-2012: BMSN participates in the 2012 Stem Cell Meeting on the Mesa. There, J. Christopher Mizer explains their business plan. Check it out!
11-19-2012: Pre-Clinical study for HemaXellerate begins.
1-24-2013: Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate.
2-5-2013: Investigational New Drug (IND) Application is filed with the FDA for HemaXellerate.
2-26-2013: A Letter of Intent (LOI) is entered into to purchase a patent for a gene silencing treatment for breast cancer.
3-12-2013: BMSN settles an old lawsuit it had.
3-18-2013: Receives the IND # from the FDA for HemaXellerate.
3-22-2013: All SEC financials are brought up-to-date and BMSN is up-listed from the Pinks to the OTC-QB.
Where we're at now
- After the IND # PR was released, there was an initial surge in PPS. But once people realized this wasn't the full IND APPROVAL some flippers moved on to the next play and the price dropped a bit.
- Some more people moved on, dropping us below a penny which caused a panic sell-off.
- That panic caused us to dip below 50 MA and shorts and people looking for cheap shares used that to induce more fear and cause a 2nd wave of panic selling.
- Today savvy investors waited like sharks at the 200MA and sniped off millions of shares. 30+ million were grabbed in 2 minutes once it hit the 200MA, which started the bounce back up.
- Once the bounce started to take form, people on the sidelines got in and now we're in full bounce mode.
Here's the chart:
Looking Forward
- Aplastic Anemia has been shown to qualify for "Orphan Drug" status. Once the IND is approved, applying for this seems likely.
- There's also a new "Breakthrough" status that the FDA has. I'm not sure if HemaXellerate qualifies, but it sounds like it may. If so, they'll probably apply for this too. If granted, it allows the treatment to become approved for market in a single round of studies, instead of the normal three!
- Clinical trials will begin for HemaXellerate on 10 human subjects.
- The gene silencing treatment for breast cancer patent is acquired, kicking off a whole new chain of events.
IMO, we should be at least at 0.01 right now, if not at multiple pennies.
BMSN! Come get some!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
